{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:43:07Z","timestamp":1788892987231,"version":"build-2803163510"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"am","delay-in-days":313,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.intimp.2024.112423","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T09:19:59Z","timestamp":1718011199000},"page":"112423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit"],"prefix":"10.1016","volume":"137","author":[{"given":"Gaelle","family":"Massoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maclaine","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Hazimeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Moukarzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuchitra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaria C.","family":"Cayton Vaught","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Segars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Soriful","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2024.112423_b0005","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.112423_b0010","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.112423_b0015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/18715281113129990053","article-title":"Anti-inflammatory treatments for chronic diseases: a review","volume":"12","author":"Laveti","year":"2013","journal-title":"Inflamm. Allergy Drug Targets"},{"issue":"24","key":"10.1016\/j.intimp.2024.112423_b0020","doi-asserted-by":"crossref","first-page":"25118","DOI":"10.1021\/acsnano.3c07817","article-title":"Unveiling the power of gabapentin-loaded nanoceria with multiple therapeutic capabilities for the treatment of dry eye disease","volume":"17","author":"Yang","year":"2023","journal-title":"ACS Nano"},{"issue":"26","key":"10.1016\/j.intimp.2024.112423_b0025","doi-asserted-by":"crossref","first-page":"2302174","DOI":"10.1002\/advs.202302174","article-title":"Poly (l-Histidine)-mediated on-demand therapeutic delivery of roughened ceria nanocages for treatment of chemical eye injury","volume":"10","author":"Yang","year":"2023","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1021\/acsnano.2c05824","article-title":"Highly retina-permeating and long-acting resveratrol\/metformin nanotherapeutics for enhanced treatment of macular degeneration","volume":"17","author":"Nguyen","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.intimp.2024.112423_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.146864","article-title":"Biofunctionalization of nanoceria with sperminated hyaluronan enhances drug delivery performance for corneal alkali burn therapy","volume":"476","author":"Ger","year":"2023","journal-title":"Chem. Eng. J."},{"issue":"5749","key":"10.1016\/j.intimp.2024.112423_b0040","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1117634","article-title":"Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite","volume":"310","author":"Platten","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.intimp.2024.112423_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2021.132409","article-title":"Therapeutic hydrogel sheets programmed with multistage drug delivery for effective treatment of corneal abrasion","volume":"429","author":"Luo","year":"2022","journal-title":"Chem. Eng. J."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0021-5198(19)32429-1","article-title":"The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts","volume":"60","author":"Suzawa","year":"1992","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112423_b0055","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.2147\/DDDT.S264715","article-title":"Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta\/SMAD2 pathway","volume":"14","author":"Kato","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2024.112423_b0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.phrs.2014.10.009","article-title":"Tranilast: a review of its therapeutic applications","volume":"91","author":"Darakhshan","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2024.112423_b0065","unstructured":"P.Y.-A.D. Min-Ji Charng, Mei-Hua Chuang, Chin-Yi Lo, Pei-Shan Chiang, Li-Heng Pao, Pharmacokinetic properties of tranilast in Chinese people, J. Food Drug Anal 10 (2002) 135-138."},{"issue":"11","key":"10.1016\/j.intimp.2024.112423_b0070","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.3390\/ijms23115878","article-title":"Analgesic effect of tranilast in an animal model of neuropathic pain and its role in the regulation of tetrahydrobiopterin synthesis","volume":"23","author":"Raman","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.2042-7158.1998.tb03304.x","article-title":"Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats","volume":"50","author":"Murakami","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112423_b0080","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3390\/ma13071675","article-title":"Development of sustained-release ophthalmic formulation based on tranilast solid nanoparticles","volume":"13","author":"Minami","year":"2020","journal-title":"Materials"},{"issue":"7","key":"10.1016\/j.intimp.2024.112423_b0085","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1021\/acsomega.9b01228","article-title":"Repurposing of tranilast for potential neuropathic pain treatment by inhibition of sepiapterin reductase in the BH4 pathway","volume":"4","author":"Moore","year":"2019","journal-title":"ACS Omega"},{"issue":"27","key":"10.1016\/j.intimp.2024.112423_b0090","doi-asserted-by":"crossref","first-page":"14300","DOI":"10.1074\/jbc.M116.722215","article-title":"Tranilast blocks the interaction between the protein S100A11 and receptor for advanced glycation end products (RAGE) V domain and inhibits cell proliferation","volume":"291","author":"Huang","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0095","doi-asserted-by":"crossref","first-page":"e8689","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP 3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bjp.0703285","article-title":"Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors","volume":"130","author":"Watanabe","year":"2000","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0021-9150(97)00275-X","article-title":"Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries","volume":"137","author":"Ward","year":"1998","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.intimp.2024.112423_b0110","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1161\/01.ATV.0000019405.84384.9C","article-title":"Tranilast prevents activation of transforming growth factor-\u03b2 system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting","volume":"22","author":"Ward","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0115","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.fertnstert.2014.05.013","article-title":"Tranilast, an orally active antiallergic compound, inhibits extracellular matrix production in human uterine leiomyoma and myometrial cells","volume":"102","author":"Islam","year":"2014","journal-title":"Fertil. Steril."},{"issue":"6","key":"10.1016\/j.intimp.2024.112423_b0120","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.ki.5000189","article-title":"Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells","volume":"69","author":"Qi","year":"2006","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0125","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1124\/mol.62.4.856","article-title":"Tranilast inhibits cytokine-induced nuclear factor \u03baB activation in vascular endothelial cells","volume":"62","author":"Spiecker","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0021-9150(95)05709-9","article-title":"Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells","volume":"121","author":"Miyazawa","year":"1996","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.intimp.2024.112423_b0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bpa.2003.12.002","article-title":"Mechanisms of the inflammatory response","volume":"18","author":"Sherwood","year":"2004","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112423_b0140","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/intimm\/dxy054","article-title":"Macrophages in inflammation, repair and regeneration","volume":"30","author":"Oishi","year":"2018","journal-title":"Int. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112423_b0145","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000347132","article-title":"Damage-associated molecular patterns control neutrophil recruitment","volume":"5","author":"Pittman","year":"2013","journal-title":"J. Innate Immun."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0155","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-065X.2012.01146.x","article-title":"PAMPs and DAMPs: signal 0s that spur autophagy and immunity","volume":"249","author":"Tang","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2024.112423_b0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fphys.2018.00113","article-title":"Neutrophil: a cell with many roles in inflammation or several cell types?","volume":"9","author":"Rosales","year":"2018","journal-title":"Front. Physiol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41423-021-00832-3","article-title":"Neutrophils in chronic inflammatory diseases","volume":"19","author":"Herrero-Cervera","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112423_b0170","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00011-004-1307-8","article-title":"Neutrophil recruitment in mast cell-dependent inflammation: inhibitory mechanisms of glucocorticoids","volume":"53","author":"Schramm","year":"2004","journal-title":"Inflamm. Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0175","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1152\/physrev.1997.77.4.1033","article-title":"Mast cells","volume":"77","author":"Metcalfe","year":"1997","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2024.112423_b0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112423_b0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1568010054022024","article-title":"Macrophages in inflammation","volume":"4","author":"Fujiwara","year":"2005","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"issue":"3","key":"10.1016\/j.intimp.2024.112423_b0190","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MOT.0000000000000313","article-title":"Role of monocytes and macrophages in regulating immune response following lung transplantation","volume":"21","author":"Chiu","year":"2016","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0195","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.intimp.2024.112423_b0200","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis","volume":"8","author":"Walton","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3831\/KPI.2020.23.009","article-title":"Current and future molecular mechanism in inflammation and arthritis","volume":"23","author":"Sharma","year":"2020","journal-title":"J Pharmacopuncture"},{"issue":"6958","key":"10.1016\/j.intimp.2024.112423_b0210","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.112423_b0215","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2024.112423_b0220","doi-asserted-by":"crossref","unstructured":"B. Kaminska, MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits, in: Biochim Biophys Acta., Netherlands, 2005,. p. 253-262.","DOI":"10.1016\/j.bbapap.2005.08.017"},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/genes4020101","article-title":"The role of mitogen-activated protein kinase-activated protein kinases (MAPKAPKs) in inflammation","volume":"4","author":"Moens","year":"2013","journal-title":"Genes (Basel)"},{"issue":"5","key":"10.1016\/j.intimp.2024.112423_b0230","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2024.112423_b0235","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/DSS.0000000000000819","article-title":"Keloids and hypertrophic scars: pathophysiology, classification, and treatment","volume":"43","author":"Berman","year":"2017","journal-title":"Dermatol. Surg."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0240","first-page":"141","article-title":"Tranilast Kissei Pharmaceutical","volume":"1","author":"Konneh","year":"1998","journal-title":"IDrugs"},{"key":"10.1016\/j.intimp.2024.112423_b0245","unstructured":"Kissei Pharmaceutical Co., L. Kissei entered into an agreement with Nuon therapeutics, Inc on tranilast (product name: Rizaben\u00ae). 2007 [cited 2023 July 16, 2023]; Available from: https:\/\/www.kissei.co.jp\/e_contents\/news\/2007\/20070723-691.html."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0250","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0021-5198(19)32428-X","article-title":"Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages","volume":"60","author":"Suzawa","year":"1992","journal-title":"Jpn. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0255","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/oxfordjournals.jbchem.a124612","article-title":"Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts","volume":"116","author":"Yamada","year":"1994","journal-title":"J. Biochem."},{"issue":"12","key":"10.1016\/j.intimp.2024.112423_b0260","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0006-2952(97)00187-1","article-title":"Suppressive effects of tranilast on the expression of inducible cyclooxygenase (COX2) in interleukin-1beta-stimulated fibroblasts","volume":"53","author":"Inoue","year":"1997","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0265","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.21873\/invivo.12886","article-title":"Nanomicelle-generating microneedles loaded with tranilast for treatment of hypertrophic scars in a rabbit model","volume":"36","author":"Chien","year":"2022","journal-title":"In Vivo"},{"issue":"9","key":"10.1016\/j.intimp.2024.112423_b0270","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/DSS.0000000000001140","article-title":"The effect of tranilast 8% liposomal gel versus placebo on post-cesarean surgical scars: a prospective double-blind split-scar study","volume":"43","author":"Kohavi","year":"2017","journal-title":"Dermatol. Surg."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0275","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/1097-0142(19920701)70:1<114::AID-CNCR2820700119>3.0.CO;2-U","article-title":"Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content","volume":"70","author":"Gustafson","year":"1992","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0280","first-page":"208","article-title":"Scleroderma with an update about clinico-pathological correlation","volume":"153","author":"Rongioletti","year":"2018","journal-title":"G. Ital. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0285","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0923-1811(94)00355-I","article-title":"Tranilast inhibits collagen synthesis in normal, scleroderma and keloid fibroblasts at a late passage culture but not at an early passage culture","volume":"9","author":"Yamada","year":"1995","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.intimp.2024.112423_b0290","doi-asserted-by":"crossref","unstructured":"Y. Tajima S Fau - Suzuki, T. Suzuki Y Fau - Inazumi, and T. Inazumi, A case of atypical localized scleroderma presenting with pseudoainhum: treatment with tranilast, an anti-fibrotic agent. Acta Derm Venereol, 76(2) (1996) 162.","DOI":"10.2340\/0001555576162162"},{"key":"10.1016\/j.intimp.2024.112423_b0295","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/CCID.S160923","article-title":"Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast","volume":"11","author":"Noakes","year":"2018","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112423_b0300","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2230.1994.tb02689.x","article-title":"Treatment of linear localized scleroderma with the anti-allergic drug, tranilast","volume":"19","author":"Taniguchi","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0305","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0310","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1006\/bbrc.1996.1508","article-title":"Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells","volume":"227","author":"Ikeda","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0315","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.22338","article-title":"Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis","volume":"48","author":"Uno","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0320","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10787-011-0117-1","article-title":"Tranilast ameliorates impaired hepatic functions in Schistosoma mansoni-infected mice","volume":"20","author":"Said","year":"2012","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21873\/invivo.11019","article-title":"Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies","volume":"31","author":"Nogueira","year":"2017","journal-title":"In Vivo"},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0330","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.HYP.31.1.181","article-title":"Interactions of transforming growth factor-\u03b2 and angiotensin II in renal fibrosis","volume":"31","author":"Border","year":"1998","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0335","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.109.136531","article-title":"Angiotensin II induces connective tissue growth factor and collagen I Expression via transforming growth factor\u2013\u03b2\u2013dependent and\u2013independent Smad pathways: the role of Smad3","volume":"54","author":"Yang","year":"2009","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.intimp.2024.112423_b0340","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1172\/JCI118304","article-title":"Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression","volume":"96","author":"Lee","year":"1995","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0345","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ki.5000054","article-title":"Renal fibrosis: new insights into the pathogenesis and therapeutics","volume":"69","author":"Liu","year":"2006","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0350","first-page":"51","article-title":"Tranilast attenuates TGF-beta1-induced epithelial-mesenchymal transition in the NRK-52E cells","volume":"27","author":"Li","year":"2014","journal-title":"Pak. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2024.112423_b0355","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3109\/00313025.2010.508784","article-title":"Tranilast modulates fibrosis, epithelial-mesenchymal transition and peritubular capillary injury in unilateral ureteral obstruction rats","volume":"42","author":"Kaneyama","year":"2010","journal-title":"Pathology"},{"issue":"10","key":"10.1016\/j.intimp.2024.112423_b0360","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1097\/01.ASN.0000139066.77892.04","article-title":"Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model","volume":"15","author":"Kelly","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112423_b0365","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/sj.ki.5000376","article-title":"Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model","volume":"69","author":"Kelly","year":"2006","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0370","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000074845","article-title":"Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy","volume":"95","author":"Mifsud","year":"2003","journal-title":"Nephron Physiol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112423_b0375","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.transproceed.2009.09.073","article-title":"Tranilast attenuates chronic cyclosporine nephrotoxicity in rats","volume":"41","author":"Tao","year":"2009","journal-title":"Transpl. Proc."},{"issue":"6","key":"10.1016\/j.intimp.2024.112423_b0380","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.intimp.2024.112423_b0385","first-page":"H2860","article-title":"Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy","volume":"293","author":"Kelly","year":"2007","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"issue":"3","key":"10.1016\/j.intimp.2024.112423_b0390","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardiores.2004.10.041","article-title":"Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta","volume":"65","author":"Martin","year":"2005","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0395","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00004872-200204000-00034","article-title":"Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension","volume":"20","author":"Hocher","year":"2002","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0400","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.hlc.2012.08.054","article-title":"Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction","volume":"22","author":"See","year":"2013","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.intimp.2024.112423_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118984","article-title":"Tranilast prevents doxorubicin-induced myocardial hypertrophy and angiotensin II synthesis in rats","volume":"267","author":"Zhan","year":"2021","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.112423_b0410","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/00004872-200405000-00024","article-title":"Tranilast attenuates myocardial fibrosis in association with suppression of monocyte\/macrophage infiltration in DOCA\/salt hypertensive rats","volume":"22","author":"Kagitani","year":"2004","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.intimp.2024.112423_b0415","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1001\/jamacardio.2022.3926","article-title":"Fundamental pathobiology of coronary atherosclerosis and clinical implications for chronic ischemic heart disease management\u2014the plaque hypothesis: a narrative review","volume":"8","author":"Stone","year":"2023","journal-title":"JAMA Cardiol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112423_b0420","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0002-8703(99)70025-6","article-title":"Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT)","volume":"138","author":"Tamai","year":"1999","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.intimp.2024.112423_b0425","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1067\/mhj.2002.120770","article-title":"The impact of tranilast on restenosis after coronary angioplasty: the second tranilast restenosis following angioplasty trial (TREAT-2)","volume":"143","author":"Tamai","year":"2002","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0430","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0002-8703(00)90304-1","article-title":"The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial","volume":"139","author":"Holmes","year":"2000","journal-title":"Am. Heart J."},{"issue":"6","key":"10.1016\/j.intimp.2024.112423_b0435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061461","article-title":"Molecular mechanisms of pulmonary fibrogenesis and its progression to lung cancer: a review","volume":"20","author":"Kinoshita","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.112423_b0440","unstructured":"FDA. Reference 16 - Food and Drug Administration Supplemental Review of Topical Tranilast, April 25, 2016. 2016 [cited 2023 July 16, 2023]; Available from: https:\/\/www.regulations.gov\/document\/FDA-2016-N-3464-0033."},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0445","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.burns.2022.03.010","article-title":"In vitro and vivo study of tranilast protects from acute respiratory distress syndrome and early pulmonary fibrosis induced by smoke inhalation","volume":"48","author":"Cui","year":"2022","journal-title":"Burns"},{"issue":"9","key":"10.1016\/j.intimp.2024.112423_b0450","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3109\/02770900903089998","article-title":"Effects of tranilast and pentoxifylline in a mouse model of chronic asthma using house dust mite antigen","volume":"46","author":"Kim","year":"2009","journal-title":"J. Asthma"},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0455","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1254\/jjp.67.279","article-title":"Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis","volume":"67","author":"Mori","year":"1995","journal-title":"Jpn. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112423_b0460","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-0030-1251475","article-title":"Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women","volume":"28","author":"Malik","year":"2010","journal-title":"Semin. Reprod. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0465","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/humupd\/dmx032","article-title":"Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics","volume":"24","author":"Islam","year":"2018","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.intimp.2024.112423_b0470","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/783289","article-title":"The extracellular matrix contributes to mechanotransduction in uterine fibroids","author":"Leppert","year":"2014","journal-title":"Obstet. Gynecol. Int."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0475","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ijgo.13102","article-title":"Epidemiology and management of uterine fibroids","volume":"149","author":"Giuliani","year":"2020","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"6","key":"10.1016\/j.intimp.2024.112423_b0480","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.fertnstert.2019.12.002","article-title":"Tranilast induces MiR-200c expression through blockade of RelA\/p65 activity in leiomyoma smooth muscle cells","volume":"113","author":"Chuang","year":"2020","journal-title":"Fertil. Steril."},{"issue":"9","key":"10.1016\/j.intimp.2024.112423_b0485","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1177\/1933719116682878","article-title":"Tranilast inhibits genes functionally involved in cell proliferation, fibrosis, and epigenetic regulation and epigenetically induces miR-29c expression in leiomyoma cells","volume":"24","author":"Chuang","year":"2017","journal-title":"Reprod. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2024.112423_b0490","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1210\/jc.2002-020444","article-title":"Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53","volume":"87","author":"Shime","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"50","key":"10.1016\/j.intimp.2024.112423_b0495","doi-asserted-by":"crossref","first-page":"e23633","DOI":"10.1097\/MD.0000000000023633","article-title":"Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I\/II study (TNAC)","volume":"99","author":"Shiozaki","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0500","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1398-9995.1979.tb01701.x","article-title":"A double blind controlled trial of N-(3',4'-dimethoxycinnamoyl) anthranilic acid on children with bronchial asthma. N-5' Study Group in Children","volume":"34","author":"Shioda","year":"1979","journal-title":"Allergy"},{"key":"10.1016\/j.intimp.2024.112423_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111844","article-title":"Anti-cancer effects of tranilast: an update","volume":"141","author":"Osman","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.intimp.2024.112423_b0510","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10120-021-01275-5","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast","volume":"25","author":"Nakamura","year":"2022","journal-title":"Gastric Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2024.112423_b0515","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1161\/01.CIR.0000028335.31300.DA","article-title":"Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial","volume":"106","author":"Holmes","year":"2002","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.intimp.2024.112423_b0520","first-page":"2471","article-title":"Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders","volume":"32","author":"Rogosnitzky","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.intimp.2024.112423_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102241","article-title":"Emerging strategies for treating gout","volume":"65","author":"Huddleston","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112423_b0530","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","article-title":"Safety and tolerability of available urate-lowering drugs: a critical review","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"8","key":"10.1016\/j.intimp.2024.112423_b0535","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","article-title":"Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial","volume":"27","author":"Lewis","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0540","article-title":"A review of pirfenidone as an anti-fibrotic in idiopathic pulmonary fibrosis and its probable role in other diseases","volume":"13","author":"Shah","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.intimp.2024.112423_b0545","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40265-021-01487-0","article-title":"Nintedanib: a review in fibrotic interstitial lung diseases","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"issue":"22","key":"10.1016\/j.intimp.2024.112423_b0550","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.intimp.2024.112423_b0555","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.intimp.2024.112423_b0560","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.intimp.2024.112423_b0565","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9779","key":"10.1016\/j.intimp.2024.112423_b0570","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2024.112423_b0575","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1080\/21655979.2021.1982322","article-title":"Tranilast inhibits angiotensin II-induced myocardial fibrosis through S100A11\/ transforming growth factor-beta (TGF-beta1)\/Smad axis","volume":"12","author":"Chen","year":"2021","journal-title":"Bioengineered"},{"issue":"5","key":"10.1016\/j.intimp.2024.112423_b0580","first-page":"7356","article-title":"Tranilast prevents renal interstitial fibrosis by blocking mast cell infiltration in a rat model of diabetic kidney disease","volume":"17","author":"Yin","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"5","key":"10.1016\/j.intimp.2024.112423_b0585","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0022-5347(05)66400-2","article-title":"Tranilast ameliorates renal tubular damage in unilateral ureteral obstruction","volume":"165","author":"Miyajima","year":"2001","journal-title":"J. Urol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T15:35:08Z","timestamp":1720280108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924009445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":117,"alternative-id":["S1567576924009445"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112423","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112423"}}